Chimeric Antigen Receptor T-cell Therapy (CAR-T): Insights into Clinical Efficacy, Emerging Perspectives, and Future Innovations in Hematology Malignancies Treatment.

Chimeric antigen receptor (CAR) T-cell therapy has improved the outcome for patients with hematological malignancies. FDA-approved CAR-T-cell medications, such as tisagenlecleucel and axicabtagene ciloleucel, have significantly increased overall survival (OS) and progression-free survival (PFS) in patients with relapsed or refractory B-cell malignancies, particularly in pediatric acute lymphoblastic leukemia and diffuse large B-cell lymphoma. However, challenges remain, in particular in translating these successes to solid tumors, owing to issues such as tumor antigen heterogeneity, the immunosuppressive tumor microenvironment and antigen escape. Efforts to improve CAR-T-cell efficacy include exploring dual-target CAR constructs and combining CAR-T cells with radiotherapy, chemotherapy, or immunomodulatory agents. Additionally, the high costs of complex manufacturing processes and side effects, including cytokine release syndrome and neurotoxicity, remain significant issues. Research efforts are now focused on optimizing CAR-T-cell design, improving patient accessibility, and identifying biomarkers to predict patient outcomes. The use of real-world evidence and advanced computational modeling further highlights the important future role of CAR-T-cell therapy in cancer treatment. Overall, CAR-T-cell therapy has improved the outcomes of patients with hematologic malignancies and has potential for use in solid tumor therapy.